Advanced Search
CHEN Dao-guang, HUANG Xue-zhen. Study on the Relationship between Hepatitis Virus(HBV) and Liver Damage in Chemotherapy of Lymphoma[J]. Cancer Research on Prevention and Treatment, 1999, 26(4): 268-269.
Citation: CHEN Dao-guang, HUANG Xue-zhen. Study on the Relationship between Hepatitis Virus(HBV) and Liver Damage in Chemotherapy of Lymphoma[J]. Cancer Research on Prevention and Treatment, 1999, 26(4): 268-269.

Study on the Relationship between Hepatitis Virus(HBV) and Liver Damage in Chemotherapy of Lymphoma

More Information
  • Objective: Observing the ralationship between HBV and liver damage in chemotherapy of Lymphoma. Methods: Among 182 cases of lymphoma, 53 cases with positive serum HBV markerwhile 129 cases without HBV marker. The liver funtion of all cases were normal before chemotherapy, effort was made to observe the patients liver function damage after chemotherapy. Results: After two phasesregular chemotherapy, the liver damage was 45.3 % (24/53) in HBV(+) group and 27.1 % (35/129) in HBV(-)group (P <0.05). Furthermore, among the patients in HBV(+)group, 10 cases were treated with Interferon alfa -2b and the others didnt use the drug . Liver function damage was 10.0 %(1/10) in the former while 53.5 %(24/43) in the latter (P <0.05). Conclusion: The cases with HBV(+) were more likely to appear liver function damage, which could be alleviated by using Interferon alfa -2b.
  • [1]
    Heimann R, Lespagnard L, Desmet V.Am Jpathol, 1995, 147(1): 233;
    [2]
    夏国豪, 张新年, 林永刚.乙肝病毒感染与恶性淋巴瘤的化疗.国外医学肿瘤学分册, 1998, 25(1): 49;
    [3]
    Repp R, Von Horsten B, Csecke A, etal. Arch Virol Suppl, 1993, 8: 103-111;
    [4]
    Faggioli P, De Paschale M, Tocci A, etal Haematologica, 1997, 82(1): 38-42;
    [5]
    Lok ASF, Liang RHS, Chiu EKW, etal. Gastroenterology, 1991, 100: 182;
    [6]
    肖若芝.淋巴瘤肝损害临床分析, 中国肿瘤临床与康复, 1996, 3(3): 22-23;
    [7]
    Cheng Ann Lii.Blood, 1996, 87(3): 202.
  • Related Articles

    [1]LUO Hong-bo, LIU Xiu-heng, CHEN Zhimin, ZHANG De-Ling. Immunohistochemical Study of COX-2 and MMP-2 in Human Renal Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2005, 32(06): 354-346. DOI: 10.3971/j.issn.1000-8578.2783
    [2]OU Wei, WU Yi long, RONG Tie hua, XIE Dan, QIAO Gui bin, WANG Si yu, YANG Xue ning. EGFR Immunohistochemical Study of Tissue Microarray in Non small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2004, 31(11): 671-673. DOI: 10.3971/j.issn.1000-8578.2087
    [3]ZHANG Jie, TIAN Bo, GE Ming-huan, et al, . Immuno-histochemical analysis on expression of HSPgp96 in renal cell carcinoma[J]. Cancer Research on Prevention and Treatment, 2003, 30(05): 376-377. DOI: 10.3971/j.issn.1000-8578.1432
    [4]CHU Xiao-yuan, CHEN Long-bang, WANG Jing-hua, et al. Studyon Expressionof E-CadherininHuman Non-SmallCell Lung cancer[J]. Cancer Research on Prevention and Treatment, 2001, 28(06): 424-425. DOI: 10.3971/j.issn.1000-8578.951
    [5]CAO Jun, GAO Ping, HUANG Ying-gui, et al. The Clinicopathological and Immunohistochemical Study of Oifactory Neuroblatoma[J]. Cancer Research on Prevention and Treatment, 2000, 27(06): 441-443. DOI: 10.3971/j.issn.1000-8578.1208
    [6]Wu Weicheng, . Prognostic value of Ki-67 Labeling Index in Renal Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 1998, 25(3): 178-180.
    [7]Liu Fengxuan, . A Mucohistochemical and Immunohistochemical study of 16 cases Primary Adenocarcinoma of the Urinary Bladder[J]. Cancer Research on Prevention and Treatment, 1997, 24(4): 225-227.
    [8]Lin Dongmei, . Clinical-pathologic characteristics of Pulmonary balstoma[J]. Cancer Research on Prevention and Treatment, 1997, 24(1): 29-30.
    [10]THE RELATIONShIIP BETWEEN PROGNOSIS AND IMMUNO-HISTOCHEMISTRY OF CEA IN GASTRIC CAREINOMA:111 CASES[J]. Cancer Research on Prevention and Treatment, 1991, 18(2): 95-98.

Catalog

    Article views (1180) PDF downloads (490) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return